Of all the explanations a woman can receive for why her IVF cycle failed, "poor egg quality" is among the most common — and among the most incompletely explained.

It is delivered, in many clinics, as a conclusion rather than a beginning. As if identifying poor egg quality as the problem is also the end of the conversation about what can be done. As if the quality of your eggs is a fixed biological fact that medicine cannot influence and you simply have to accept.

For some women, in some circumstances, this is partially true. Age-related decline in egg quality is a real biological phenomenon, and there are limits to what can be done to reverse it. But for many women — perhaps the majority of those who receive this explanation — poor egg quality is not a fixed and irreversible condition. It is the result of one or more specific, identifiable factors — factors that can be investigated, addressed, and in many cases meaningfully improved before the next IVF cycle.

The question this article answers is the one every woman deserves to have fully addressed after receiving this diagnosis: what actually causes poor egg quality, and is there anything that can genuinely be done about it?

What Does "Egg Quality" Actually Mean?

Before exploring causes and corrections, it is worth being precise about what egg quality means — because the term is used loosely in fertility medicine and encompasses several distinct biological concepts that have different causes and different treatment implications.

Egg quality refers, most fundamentally, to the developmental competence of an egg — its ability to be fertilized by a sperm, to undergo normal cell division after fertilization, to develop into a viable embryo, and ultimately to result in a healthy pregnancy. An egg with high developmental competence will fertilize reliably, produce an embryo that develops well through the blastocyst stage, and have a high probability of implanting successfully when transferred. An egg with low developmental competence may fail to fertilize, may fertilize but produce an embryo that arrests in development before reaching a transferable stage, or may produce an embryo that transfers and implants briefly but cannot sustain a pregnancy.

The most important biological determinant of developmental competence is chromosomal integrity — whether the egg carries the correct number of chromosomes. Chromosomally normal eggs — euploid eggs — have the capacity to produce viable embryos. Chromosomally abnormal eggs — aneuploid eggs — may fertilize and even produce seemingly normal embryos in early culture, but they cannot sustain a pregnancy. The proportion of aneuploid eggs increases with maternal age — this is the primary biological mechanism behind age-related fertility decline.

But chromosomal integrity is not the only component of egg quality. The energy reserves within the egg — provided by its mitochondria — determine whether the egg can sustain the intensive cellular activity of fertilization and early embryonic development. The developmental environment in which the egg matured — the follicular fluid, the hormonal milieu, the inflammatory state of the ovary — shapes the egg's quality before retrieval. And the laboratory environment in which the egg is handled and fertilized after retrieval affects how well its developmental potential is preserved.

Understanding which of these components is driving poor egg quality in a specific patient is the essential first step in determining what can actually be done about it.

Cause One: Age and the Inevitable Biology

Age is the most discussed cause of poor egg quality — and the most accurately described, because the relationship between advancing maternal age and declining egg quality is one of the most robustly established facts in reproductive medicine.

As a woman ages, the proportion of her eggs that carry chromosomal abnormalities increases. At age 25, approximately 20 to 25 percent of eggs are chromosomally abnormal. By age 35, this proportion has risen to approximately 40 percent. By age 40, more than half of eggs may be chromosomally abnormal. By age 43 or 44, the proportion of chromosomally abnormal eggs may exceed 80 percent.

This progression is not reversible — it is a fundamental aspect of the biology of human female reproduction. It is also the reason that IVF success rates decline with advancing maternal age even when stimulation produces a reasonable number of eggs, because a higher proportion of the eggs retrieved are carrying chromosomal abnormalities that prevent viable embryo development.

However — and this is the critical point that the "poor egg quality" explanation often fails to make — age-related egg quality decline does not mean that all eggs are poor quality. Even in older women, a proportion of eggs will be chromosomally normal and capable of producing viable embryos. The clinical challenge is not that age makes pregnancy impossible, but that it reduces the proportion of eggs capable of producing viable embryos — meaning that more eggs need to be retrieved to obtain the same number of viable embryos, and that more cycles may be needed to achieve success.

This distinction matters enormously for the clinical approach. If the reason for poor egg quality is age-related aneuploidy, the most evidence-based response is not to give up but to optimize stimulation to retrieve the maximum number of eggs possible, and to use PGT-A — preimplantation genetic testing — to identify the chromosomally normal embryos among those retrieved, rather than transferring embryos blindly and hoping the transferred embryo happens to be euploid.

Cause Two: Stimulation Protocol Mismatch

Here is a cause of poor egg quality that is almost never communicated to patients — and that is entirely within the control of the treating doctor.

The quality of eggs retrieved in an IVF cycle is profoundly affected by the stimulation protocol used — the specific medications, doses, timing, and monitoring approach that drives follicle development. A protocol that is poorly matched to a patient's specific ovarian physiology can produce eggs that are suboptimal in quality even when the eggs themselves are biologically capable of better.

Over-stimulation is one of the most common protocol errors. When the ovarian response to gonadotropins is excessive — producing very large numbers of follicles — the individual follicles often do not develop as uniformly or as completely as they would in a more moderate response. Eggs from over-stimulated cycles are often retrieved at a less mature stage, or are exposed to an abnormal hormonal environment during maturation, both of which compromise their developmental competence.

Under-stimulation produces a different problem — too few eggs retrieved to give a reasonable chance of obtaining viable embryos.

Timing the trigger injection — the injection that completes the final maturation of eggs before retrieval — is equally critical. A trigger given too early retrieves immature eggs that cannot be fertilized. A trigger given too late retrieves eggs that have already begun to degrade. The window between these extremes is specific to each individual cycle and each individual patient, and identifying it correctly requires careful, experienced monitoring.

Different stimulation protocols — antagonist protocol, long agonist protocol, mini-stimulation, natural cycle — have different profiles of advantages and disadvantages for different patient types. The protocol that produces the best egg quality in a 30-year-old woman with high ovarian reserve is not the same protocol that produces the best egg quality in a 39-year-old woman with low ovarian reserve. This is not controversial — it is simply the individualized application of clinical knowledge that every patient deserves and that many clinics do not apply.

When poor egg quality has been reported in previous IVF cycles and the cause is not clearly age-related, reviewing the stimulation protocol in detail — the medications used, the starting dose, the monitoring findings, the trigger timing, and the retrieved egg maturity rates — is one of the first things Dr. Soni does in a second opinion consultation. Protocol mismatch as a contributing cause is found frequently, and it is entirely correctable.

Cause Three: Conditions Affecting the Ovarian Environment

Several medical conditions create an ovarian environment that is hostile to egg development — independent of the stimulation protocol used. Understanding and addressing these conditions before the next IVF cycle can produce meaningful improvements in egg quality.

Endometriosis is among the most significant. The inflammatory process of endometriosis — which involves the presence of endometrial tissue outside the uterus, typically on or near the ovaries — creates a local environment rich in oxidative stress, inflammatory cytokines, and toxic metabolic byproducts. This environment directly damages developing eggs within the ovarian follicles. Women with endometriosis consistently show higher rates of poor egg quality, lower fertilization rates, and poorer embryo development than women without the condition — even after controlling for other factors. Surgical treatment of endometriosis, where appropriate, and medical management to reduce inflammatory burden before IVF can partially mitigate this effect.

PCOS — polycystic ovary syndrome — presents a different challenge. Women with PCOS often produce large numbers of eggs in IVF stimulation — which sounds advantageous — but many of these eggs are immature or developmentally suboptimal. The hormonal environment of a PCOS ovary, characterized by elevated androgens and abnormal follicle development dynamics, creates conditions in which eggs may not complete maturation properly. Careful protocol selection — often including pre-treatment with metformin or other insulin-sensitizing agents, and the use of specific stimulation approaches designed for PCOS patients — can significantly improve egg maturity and quality in women with this condition.

Diminished ovarian reserve — characterized by low AMH, low antral follicle count, and often elevated FSH — is a condition in which the ovarian pool has been depleted, leaving fewer follicles to develop in response to stimulation. Diminished reserve does not uniformly mean poor egg quality — some women with very low AMH produce a small number of eggs that are of excellent quality. But the combination of few eggs and compromised ovarian function does often produce eggs with reduced developmental competence. Stimulation approaches designed specifically for low-reserve patients — including use of growth hormone supplementation, modified natural cycle protocols, or mini-stimulation — can in some cases improve the quality of the limited eggs available.

Thyroid dysfunction has a direct effect on ovarian function and egg development. Thyroid hormones play a role in follicle development, and both hypothyroidism and hyperthyroidism, even in subclinical forms, can compromise egg quality. Optimizing thyroid function before IVF — to a TSH below 2.5 mIU/L by fertility-specific standards — is a simple intervention with documented relevance to egg quality and subsequent cycle outcomes.

Cause Four: Nutritional and Mitochondrial Factors

Mitochondria — the energy-producing organelles within cells — are present in extraordinarily high numbers in human eggs compared to any other cell in the body. This is not coincidental. The energy demands of fertilization, the dramatic reorganization of chromosomes during the first cell division, and the rapid proliferation of cells in early embryo development all depend on the mitochondrial energy supply within the egg.

When mitochondrial function is compromised — by age, by nutritional deficiency, by toxic exposures, or by other factors — the egg may lack the energy reserves to complete fertilization and early development successfully. This manifests clinically as poor fertilization rates, high rates of embryo arrest at the two-cell or four-cell stage, or failure of embryos to reach blastocyst stage despite apparently normal fertilization.

Several nutritional interventions have a documented evidence base for supporting mitochondrial function in eggs.

CoQ10 — coenzyme Q10 — is a mitochondrial cofactor that plays a direct role in the cellular energy production pathway. CoQ10 levels in eggs decline with age, and supplementation in the months before IVF has been associated with improved egg quality and embryo development in multiple studies. The dose required for meaningful mitochondrial support is typically higher than what is found in standard multivitamins — 400 to 600 milligrams daily of the ubiquinol form is commonly recommended, for at least two to three months before the cycle.

Vitamin D is essential for follicle development and has been associated with egg quality and IVF outcomes in observational studies. Deficiency is extraordinarily common in India — including in Chhattisgarh — and correction of deficiency before an IVF cycle is a simple, inexpensive intervention that is warranted in most patients.

DHEA — dehydroepiandrosterone — is an androgen precursor that has been studied specifically in women with diminished ovarian reserve. The evidence base is not uniform, but a meaningful number of studies have shown improvements in egg number and quality in low-reserve patients who supplement with DHEA for two to three months before IVF. Dr. Soni considers DHEA supplementation on an individualized basis — it is not appropriate for every patient, but for selected low-reserve patients it forms part of an evidence-based pre-cycle optimization strategy.

Antioxidants more broadly — including vitamin C, vitamin E, alpha-lipoic acid, and omega-3 fatty acids — reduce oxidative stress in the follicular environment and support the cellular integrity of developing eggs. In women with endometriosis, where oxidative stress is particularly elevated, antioxidant supplementation has a specific and well-reasoned rationale.

Cause Five: Laboratory Factors After Retrieval

Egg quality at the time of retrieval is the starting point — but what happens to the egg in the laboratory after retrieval also affects developmental outcomes.

Eggs are extraordinarily sensitive to temperature changes, light exposure, pH variations, and mechanical disruption. The process of denudation — removing the surrounding cumulus cells from the egg before ICSI — must be performed with precisely the right enzyme concentration and technique, because over-exposure strips the egg's protective zona and causes damage, while under-exposure leaves residual cells that interfere with the ICSI process.

The culture medium in which eggs and embryos develop must be of the highest quality — correctly formulated, properly pH-equilibrated, and free from any contamination. The incubator in which embryos develop must maintain precise temperature and atmospheric conditions, with minimal disturbance to developing embryos. Time-lapse incubators — which allow continuous monitoring without removing embryos for observation — significantly reduce the mechanical and environmental disruption to developing embryos.

These laboratory factors are invisible to patients but directly relevant to egg and embryo quality outcomes. When poor fertilization rates or high rates of embryo arrest have been reported in previous cycles, and when clinical factors do not fully explain the laboratory findings, laboratory quality at the previous clinic is worth considering as a contributing factor.

Can Egg Quality Be Corrected? The Honest Answer

The honest answer — which this article has been building toward throughout — is: it depends on the cause, and in many cases yes, meaningfully.

Age-related chromosomal aneuploidy cannot be reversed. But its impact can be managed through PGT-A screening, through stimulation optimization to maximize egg numbers, and in some cases through donor egg IVF when the proportion of viable eggs is too low to make further autologous attempts justified.

Protocol mismatch can be fully corrected — with a redesigned, individualized stimulation protocol based on the patient's specific ovarian characteristics.

Endometriosis-related egg quality compromise can be partially mitigated through surgical and medical management of the underlying condition before the cycle.

PCOS-related immaturity can be significantly improved through appropriate protocol selection and pre-treatment optimization.

Nutritional and mitochondrial deficiencies can be addressed through targeted supplementation — CoQ10, vitamin D, DHEA where indicated, and antioxidants — implemented with sufficient lead time before the cycle.

Thyroid dysfunction can be corrected through medication adjustment, with a meaningful improvement in the ovarian environment for subsequent cycles.

What none of these corrections require is simply trying the same cycle again and hoping for a different result. They require a specific, investigative approach that identifies which factors are contributing to poor egg quality in that individual patient, and that addresses those factors specifically before the next cycle begins.

What Dr. Soni Does Differently for Poor Egg Quality Cases

At Metro IVF in Ambikapur, poor egg quality is never treated as a dead-end diagnosis. It is treated as the beginning of an investigation.

When a patient arrives with a history of poor egg quality in previous cycles — whether diagnosed based on fertilization failure, poor embryo development, or consistently low numbers of viable embryos despite adequate stimulation — Dr. Soni begins with a systematic review of every factor that could be contributing.

He reviews the previous stimulation protocol in detail — the medications, the doses, the monitoring findings, the trigger timing, and the egg maturity and fertilization rates — to identify protocol mismatch as a potential correctable cause.

He assesses the full hormonal picture — AMH, antral follicle count, FSH, LH, estradiol, thyroid function, and DHEA-S — to understand the ovarian environment and identify any systemic factors affecting follicle development.

He asks specifically about endometriosis, PCOS, and other conditions known to compromise the ovarian environment, and recommends appropriate management where indicated.

He discusses nutritional supplementation — CoQ10, vitamin D, antioxidants — with specific doses and timing based on the patient's individual deficiency profile and the lead time available before the next cycle.

And he designs a stimulation protocol that is specifically tailored to the patient's ovarian characteristics — not a standard template applied because it works for most patients, but an individualized approach built for this patient's specific biology.

This is not a guarantee of success. Egg quality, particularly in older women, has biological limits that medicine cannot fully overcome. But for the significant proportion of women whose poor egg quality has a correctable contributing cause — a protocol that was wrong for their biology, a nutritional deficiency that was never addressed, a medical condition that was never optimized before the cycle — this investigative, individualized approach produces outcomes that are meaningfully better than repeating the same cycle that failed before.

Your Next Step

If you have been told that poor egg quality is the reason your IVF cycle failed — and if that explanation was delivered without a specific investigation into why your egg quality was poor and what might be done differently — you have not received the complete picture.

At Metro IVF in Ambikapur, Dr. Ashish Soni provides exactly that complete picture — a thorough investigation of the causes of poor egg quality specific to your case, and a treatment plan designed around what that investigation actually finds.

The conversation about poor egg quality does not have to end at the diagnosis. For many women, it is the beginning of a different, better-designed approach that produces a very different outcome.

Metro IVF Test Tube Baby Center Ambikapur, Chhattisgarh metrofertility.in Led by Dr. Ashish Soni — North India's First Fertility Super Specialist

Poor egg quality does not have to be the end of the story. Book your consultation with Dr. Soni today — and find out what can genuinely be done.